Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT05 PK Similarity to Simponi in Healthy Adults
NCT05632211Phase 1Completed
- Sponsor
- Alvotech
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of AVT05 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and 1 more (3 arms), sponsored by Alvotech. Primary endpoint: Pharmacokinetic Similarity of AVT05 With US Licensed and EU Approved Simponi. Started Dec 2022; status: completed.
02
Drugs
AVT05
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05632211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632211.